# Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.

> **NCT03497377** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** 18F-DCFPyL Injection
- **DRUG:** 18F-NaF

## Key facts

- **NCT ID:** NCT03497377
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-16
- **Primary completion:** 2020-04
- **Final completion:** 2020-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03497377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03497377, "Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03497377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*